Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Inclusion Criteria:

* Histologically confirmed stage II or stage IIIA non-small cell lung cancer (NSCLC) and meet the requirements for R0 resection;
* American Society of Anesthesiologists (ASA): I-III, age ≥18 years, body mass index (BMI): 18.5-30;
* Normal function of Coagulation and vital organs such as heart, lungs, kidney, and liver;
* Eligible to receive platinum-containing two-drug chemotherapy;
* Sign the informed consent form

Exclusion Criteria

* Prior treatment of any kind for current lung cancer, including chemotherapy, radiation or targeted therapy;
* Preoperative opioid analgesia;
* Severe chronic or active infection requiring systemic antibacterial, antifungal or antiviral therapy, including tuberculosis infection;
* History of antipsychotic medication in the last 6 months;
* Preoperative Mini-mental state examination (MMSE) score \<23